From Genome Exploration to Drug Development

FDA's plan to establish pharmacogenomic policies spurs concerns among manufacturers, particularly in regard to how the policies will affect new-drug testing and approval.

Related Content:

Regulatory WatchPharmaceutical Technology-06-02-2003

Biosimilars Move to Center Stage

CMA Fines Advanz for Over-Pricing Liothyronine Tablets

FDA Prioritizes Vaccine Review and Process Improvements